Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and toxicity profile of bispecific antibodies for multiple myeloma including teclistamab and elranatamab, discussing overall response rates (ORR), cytokine release syndrome (CRS) and infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.